Oramed Pharmaceuticals (ORMP)
Develops oral formulations for insulin and other therapeutic proteins.
Something off on this page? Send us feedback.
Develops oral-delivery formulations for therapeutic proteins, with oral insulin as its core development program. Its current context also includes strategic healthcare and life-sciences investments, financing, and real-estate transactions.
Develops oral-delivery formulations for therapeutic proteins, designed to protect insulin and other proteins through the gastrointestinal environment without chemically or biologically modifying the protein. No commercialized therapeutic product is described in the current filing.
Oral insulin is the core development program and ORMD-0801 was its former flagship candidate. A U.S. Phase 3 study reported in 2023 did not meet its primary or secondary endpoint; the company now intends a narrower planned U.S. trial through OraTech to test formulation robustness and refine patient selection.
Alongside pharmaceutical development, capital is allocated to strategic healthcare and life-sciences investments as well as financing and real-estate transactions. Clinical execution, regulatory approvals, and outcomes from financial investments shape the business.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $50.6M · Total debt $733.0K · Total assets $369.6M · Shareholders' equity $317.5M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- $78.2M
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jan 16, 2026 | Jan 16 | Jan 26 | $0.25 | special dividend |
| Institutions64 holders · as of Mar 31, 2026 | 31.83% | 13.24M shares | |
| Insiders9 holders · as of Jul 2, 2026 | 17.62% | 7.33M shares | |
| Otherremainder | 50.55% | 21.03M shares |
41.60M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Nadav Kidron1Insiderdirector, officer: President and CEO | 9.15% | 3.12M | 13Dfiled Mar 31, 2026 ↗ |
BML Capital Management, LLCInstitution | 7.61% | 3.17M | 13Fas of Mar 31, 2026 |
Aquamarine Financial (Cayman) LtdInstitution | 5.08% | 2.11M | 13Fas of Mar 31, 2026 |
BML Investment Partners, L.P.Institution | 4.92% | 2.05M | 13Gfiled Sep 16, 2024 ↗ |
Mercer Global Advisors Inc /AdvInstitution | 4.59% | 1.91M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Nadav Kidron's transaction reports restate only vehicles that traded; the 2025 ownership statement (3.12M) plus the 690.8K net shares acquired since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Avraham Gabay | officer: Chief Financial Officer | −73,360 | $4.51 |
| Jul 1, 2026 | Joshua Hexter | officer: COO & CBO | −137,000 | $4.46 |
- Novo Nordisk (ADR)
Diabetes leader across insulin and oral GLP-1 therapy
- Eli Lilly
Large diabetes franchise spanning insulin and incretin medicines
- Sanofi (ADR)
Established basal-insulin supplier with Lantus and Toujeo
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals | $5.00 | −1.38% | $207.5M | 1.2 | — | — | — |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Sanofi (ADR) | $44.57 | +0.24% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Median | 38.9 | 23.6 | 4.1 | +11.2% |